InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,319.31
(
2.30%
)
US TECH 100
17,963.20
(
3.29%
)
Dow Jones
39,446.49
(
1.76%
)
Brent Oil
78.74
(
0.46%
)
Bitcoin
61,817.74
(
12.33%
)
Post# of 81470
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

IIIverson

Send PM Follow Ignore
Followers 45
Posts 13231
Boards Moderated 1
Alias Born 07/20/2009

IIIverson

Re: Tanaka post# 76771

Monday, 09/13/2010 8:42:44 AM

Monday, September 13, 2010 8:42:44 AM

Post# of 81470
GOT SOME GOOD NEWS...



ARIA HaS AcTiVAtIONZ$$$$ (however BB says it)

ARIAD Announces Initiation of Ponatinib (AP24534) Pivotal Trial in Drug-Resistant or Intolerant Chronic Myeloid Leukemia
0 minutes ago - BusinessWire

--~ Regulatory agency agreement secured for trial design
--~ Conference call today at 9:00 a.m. ET
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the initiation of the pivotal Phase 2 clinical trial of its investigational pan-BCR-ABL inhibitor, ponatinib (previously known as AP24534), in patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL). The P
ARIAD Announces Initiation Of Ponatinib (AP24534) Pivotal Trial In Drug-Resistant Or Intolerant Chronic Myeloid Leukemia
0 minutes ago - T
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up